Results for
"[search-keyword]"
Sponsor content
165 result(s) found, displaying 31 to 40
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 1500 IU powder for injection vial with solvent.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 500 IU powder for injection vial with solvent.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 1000 IU powder for injection vial with solvent.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 2000 IU powder for injection vial with solvent.
-
Australian Public Assessment Report (AusPAR)Esperoct (turoctocog alfa pegol) has been approved to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A.
-
Prescription medicine decision summaryAlhemo (concizumab) is approved to prevent haemophilia.
-
Prescription medicine registrationActive ingredients: somapacitan.
-
Prescription medicine registrationActive ingredients: concizumab.
-
Prescription medicine decision summaryTGA decision: Alhemo is approved where prophylaxis is required to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have haemophilia B.
-
Prescription medicine registrationActive ingredients: concizumab.